Cancer Gene Therapy Market

1. INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           RESEARCH METHODOLOGY

1.2.1             SECONDARY RESEARCH

1.2.2             DATA ANALYSIS FRAMEWORK

1.2.3             MARKET SIZE ESTIMATION

1.2.4             FORECASTING

1.2.5             PRIMARY RESEARCH AND DATA VALIDATION

2. MARKET SNAPSHOT, 2022-2030 MILLION USD

2.1.           MARKET SNAPSHOT

3. PORTER’S FIVE FORCE MODEL ANALYSIS

4. MARKET DYNAMICS

4.1.           GROWTH DRIVERS

4.1.1             DRIVER 1

4.1.2             DRIVER 2

4.1.3             DRIVER 3

4.1.4             DRIVER 4

4.2.           CHALLENGES

4.2.1             CHALLENGE 1

4.2.2             CHALLENGE 2

4.3.           OPPORTUNITIES

4.3.1             OPPORTUNITY 1

4.3.2             OPPORTUNITY 2

5. GLOBAL  CANCER GENE THERAPY MARKET, BY THERAPY

5.1.           OVERVIEW

5.2.           GENE INDUCED IMMUNOTHERAPY

5.2.1             GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

5.2.1.1        ADENOVIRUS MARKET, BY REGION

5.2.1.1.1        NORTH AMERICA ADENOVIRUS MARKET, BY COUNTRY

5.2.1.1.2        EUROPE ADENOVIRUS MARKET, BY COUNTRY

5.2.1.1.3        ASIA-PACIFIC ADENOVIRUS MARKET, BY COUNTRY

5.2.1.1.4        REST OF WORLD ADENOVIRUS MARKET, BY COUNTRY

5.2.1.2        LENTIVIRUS MARKET, BY REGION

5.2.1.2.1        NORTH AMERICA LENTIVIRUS MARKET, BY COUNTRY

5.2.1.2.2        EUROPE LENTIVIRUS MARKET, BY COUNTRY

5.2.1.2.3        ASIA-PACIFIC LENTIVIRUS MARKET, BY COUNTRY

5.2.1.2.4        REST OF WORLD LENTIVIRUS MARKET, BY COUNTRY

5.2.1.3        RETRO VIRUS MARKET, BY REGION

5.2.1.3.1        NORTH AMERICA RETRO VIRUS MARKET, BY COUNTRY

5.2.1.3.2        EUROPE RETRO VIRUS MARKET, BY COUNTRY

5.2.1.3.3        ASIA-PACIFIC RETRO VIRUS MARKET, BY COUNTRY

5.2.1.3.4        REST OF WORLD RETRO VIRUS MARKET, BY COUNTRY

5.2.1.4        ADENO ASSOCIATED VIRUS MARKET, BY REGION

5.2.1.4.1        NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY

5.2.1.4.2        EUROPE ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY

5.2.1.4.3        ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY

5.2.1.4.4        REST OF WORLD ADENO ASSOCIATED VIRUS MARKET, BY COUNTRY

5.2.1.5        HERPES SIMPLEX VIRUS MARKET, BY REGION

5.2.1.5.1        NORTH AMERICA HERPES SIMPLEX VIRUS MARKET, BY COUNTRY

5.2.1.5.2        EUROPE HERPES SIMPLEX VIRUS MARKET, BY COUNTRY

5.2.1.5.3        ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET, BY COUNTRY

5.2.1.5.4        REST OF WORLD HERPES SIMPLEX VIRUS MARKET, BY COUNTRY

5.2.1.6        ALPHA VIRUS MARKET, BY REGION

5.2.1.6.1        NORTH AMERICA ALPHA VIRUS MARKET, BY COUNTRY

5.2.1.6.2        EUROPE ALPHA VIRUS MARKET, BY COUNTRY

5.2.1.6.3        ASIA-PACIFIC ALPHA VIRUS MARKET, BY COUNTRY

5.2.1.6.4        REST OF WORLD ALPHA VIRUS MARKET, BY COUNTRY

5.2.1.7        VACCINIA VIRUS MARKET, BY REGION

5.2.1.7.1        NORTH AMERICA VACCINIA VIRUS MARKET, BY COUNTRY

5.2.1.7.2        EUROPE VACCINIA VIRUS MARKET, BY COUNTRY

5.2.1.7.3        ASIA-PACIFIC VACCINIA VIRUS MARKET, BY COUNTRY

5.2.1.7.4        REST OF WORLD VACCINIA VIRUS MARKET, BY COUNTRY

5.2.1.8        SIMIAN VIRUS MARKET, BY REGION

5.2.1.8.1        NORTH AMERICA SIMIAN VIRUS MARKET, BY COUNTRY

5.2.1.8.2        EUROPE SIMIAN VIRUS MARKET, BY COUNTRY

5.2.1.8.3        ASIA-PACIFIC SIMIAN VIRUS MARKET, BY COUNTRY

5.2.1.8.4        REST OF WORLD SIMIAN VIRUS MARKET, BY COUNTRY

5.2.1.9        OTHERS MARKET, BY REGION

5.2.1.9.1        NORTH AMERICA OTHERS MARKET, BY COUNTRY

5.2.1.9.2        EUROPE OTHERS MARKET, BY COUNTRY

5.2.1.9.3        ASIA-PACIFIC OTHERS MARKET, BY COUNTRY

5.2.1.9.4        REST OF WORLD OTHERS MARKET, BY COUNTRY

5.2.2             GENE INDUCED IMMUNOTHERAPY MARKET, BY REGION

5.2.2.1        NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY

5.2.2.2        EUROPE GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY

5.2.2.3        ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY

5.2.2.4        REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET, BY COUNTRY

5.3.           ONCOLYTIC VIROTHERAPY

5.3.1             GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

5.3.1.1        DELIVERY OF CYTOKINES GENE MARKET, BY REGION

5.3.1.1.1        NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY

5.3.1.1.2        EUROPE DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY

5.3.1.1.3        ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY

5.3.1.1.4        REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET, BY COUNTRY

5.3.1.2        DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY REGION

5.3.1.2.1        NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY

5.3.1.2.2        EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY

5.3.1.2.3        ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY

5.3.1.2.4        REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET, BY COUNTRY

5.3.2             ONCOLYTIC VIROTHERAPY MARKET, BY REGION

5.3.2.1        NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY

5.3.2.2        EUROPE ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY

5.3.2.3        ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY

5.3.2.4        REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET, BY COUNTRY

5.4.           GENE TRANSFER

5.4.1             GLOBAL GENE TRANSFER MARKET, BY THERAPY

5.4.1.1        ELECTROPORATION MARKET, BY REGION

5.4.1.1.1        NORTH AMERICA ELECTROPORATION MARKET, BY COUNTRY

5.4.1.1.2        EUROPE ELECTROPORATION MARKET, BY COUNTRY

5.4.1.1.3        ASIA-PACIFIC ELECTROPORATION MARKET, BY COUNTRY

5.4.1.1.4        REST OF WORLD ELECTROPORATION MARKET, BY COUNTRY

5.4.1.2        SONOPORTION MARKET, BY REGION

5.4.1.2.1        NORTH AMERICA SONOPORTION MARKET, BY COUNTRY

5.4.1.2.2        EUROPE SONOPORTION MARKET, BY COUNTRY

5.4.1.2.3        ASIA-PACIFIC SONOPORTION MARKET, BY COUNTRY

5.4.1.2.4        REST OF WORLD SONOPORTION MARKET, BY COUNTRY

5.4.1.3        MAGNETOFECTION MARKET, BY REGION

5.4.1.3.1        NORTH AMERICA MAGNETOFECTION MARKET, BY COUNTRY

5.4.1.3.2        EUROPE MAGNETOFECTION MARKET, BY COUNTRY

5.4.1.3.3        ASIA-PACIFIC MAGNETOFECTION MARKET, BY COUNTRY

5.4.1.3.4        REST OF WORLD MAGNETOFECTION MARKET, BY COUNTRY

5.4.1.4        GENE GUN MARKET, BY REGION

5.4.1.4.1        NORTH AMERICA GENE GUN MARKET, BY COUNTRY

5.4.1.4.2        EUROPE GENE GUN MARKET, BY COUNTRY

5.4.1.4.3        ASIA-PACIFIC GENE GUN MARKET, BY COUNTRY

5.4.1.4.4        REST OF WORLD GENE GUN MARKET, BY COUNTRY

5.4.2             GENE TRANSFER MARKET, BY REGION

5.4.2.1        NORTH AMERICA GENE TRANSFER MARKET, BY COUNTRY

5.4.2.2        EUROPE GENE TRANSFER MARKET, BY COUNTRY

5.4.2.3        ASIA-PACIFIC GENE TRANSFER MARKET, BY COUNTRY

5.4.2.4        REST OF WORLD GENE TRANSFER MARKET, BY COUNTRY

6. GLOBAL  CANCER GENE THERAPY MARKET, BY REGION

6.1.           OVERVIEW

6.2.           NORTH AMERICA

6.2.1             NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY

6.2.1.1        NORTH AMERICA  GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.2.1.2        NORTH AMERICA  ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.2.1.3        NORTH AMERICA  GENE TRANSFER MARKET, BY THERAPY

6.2.2             NORTH AMERICA CANCER GENE THERAPY, MARKET BY COUNTRY

6.2.2.1        U.S

6.2.2.1.1        U.S CANCER GENE THERAPY MARKET, BY THERAPY

6.2.2.1.1.1. U.S GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.2.2.1.1.2. U.S ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.2.2.1.1.3. U.S GENE TRANSFER MARKET, BY THERAPY

6.2.2.2        CANADA

6.2.2.2.1        CANADA CANCER GENE THERAPY MARKET, BY THERAPY

6.2.2.2.1.1. CANADA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.2.2.2.1.2. CANADA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.2.2.2.1.3. CANADA GENE TRANSFER MARKET, BY THERAPY

6.2.2.3        MEXICO

6.2.2.3.1        MEXICO CANCER GENE THERAPY MARKET, BY THERAPY

6.2.2.3.1.1. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.2.2.3.1.2. MEXICO ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.2.2.3.1.3. MEXICO GENE TRANSFER MARKET, BY THERAPY

6.3.           EUROPE

6.3.1             EUROPE CANCER GENE THERAPY MARKET, BY THERAPY

6.3.1.1        EUROPE  GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.1.2        EUROPE  ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.1.3        EUROPE  GENE TRANSFER MARKET, BY THERAPY

6.3.2             EUROPE CANCER GENE THERAPY, MARKET BY COUNTRY

6.3.2.1        GERMANY

6.3.2.1.1        GERMANY CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.1.1.1. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.1.1.2. GERMANY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.1.1.3. GERMANY GENE TRANSFER MARKET, BY THERAPY

6.3.2.2        FRANCE

6.3.2.2.1        FRANCE CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.2.1.1. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.2.1.2. FRANCE ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.2.1.3. FRANCE GENE TRANSFER MARKET, BY THERAPY

6.3.2.3        UK

6.3.2.3.1        UK CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.3.1.1. UK GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.3.1.2. UK ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.3.1.3. UK GENE TRANSFER MARKET, BY THERAPY

6.3.2.4        ITALY

6.3.2.4.1        ITALY CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.4.1.1. ITALY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.4.1.2. ITALY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.4.1.3. ITALY GENE TRANSFER MARKET, BY THERAPY

6.3.2.5        SPAIN

6.3.2.5.1        SPAIN CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.5.1.1. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.5.1.2. SPAIN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.5.1.3. SPAIN GENE TRANSFER MARKET, BY THERAPY

6.3.2.6        REST OF EUROPE

6.3.2.6.1        REST OF EUROPE CANCER GENE THERAPY MARKET, BY THERAPY

6.3.2.6.1.1. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.3.2.6.1.2. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.3.2.6.1.3. REST OF EUROPE GENE TRANSFER MARKET, BY THERAPY

6.4.           ASIA-PACIFIC

6.4.1             ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY

6.4.1.1        ASIA-PACIFIC  GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.1.2        ASIA-PACIFIC  ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.1.3        ASIA-PACIFIC  GENE TRANSFER MARKET, BY THERAPY

6.4.2             ASIA-PACIFIC CANCER GENE THERAPY, MARKET BY COUNTRY

6.4.2.1        JAPAN

6.4.2.1.1        JAPAN CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.1.1.1. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.1.1.2. JAPAN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.1.1.3. JAPAN GENE TRANSFER MARKET, BY THERAPY

6.4.2.2        CHINA

6.4.2.2.1        CHINA CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.2.1.1. CHINA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.2.1.2. CHINA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.2.1.3. CHINA GENE TRANSFER MARKET, BY THERAPY

6.4.2.3        AUSTRALIA

6.4.2.3.1        AUSTRALIA CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.3.1.1. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.3.1.2. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.3.1.3. AUSTRALIA GENE TRANSFER MARKET, BY THERAPY

6.4.2.4        INDIA

6.4.2.4.1        INDIA CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.4.1.1. INDIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.4.1.2. INDIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.4.1.3. INDIA GENE TRANSFER MARKET, BY THERAPY

6.4.2.5        SOUTH KOREA

6.4.2.5.1        SOUTH KOREA CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.5.1.1. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.5.1.2. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.5.1.3. SOUTH KOREA GENE TRANSFER MARKET, BY THERAPY

6.4.2.6        TAIWAN

6.4.2.6.1        TAIWAN CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.6.1.1. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.6.1.2. TAIWAN ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.6.1.3. TAIWAN GENE TRANSFER MARKET, BY THERAPY

6.4.2.7        REST OF ASIA-PACIFIC

6.4.2.7.1        REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY

6.4.2.7.1.1. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.4.2.7.1.2. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.4.2.7.1.3. REST OF ASIA-PACIFIC GENE TRANSFER MARKET, BY THERAPY

6.5.           REST OF WORLD

6.5.1             REST OF WORLD CANCER GENE THERAPY MARKET, BY THERAPY

6.5.1.1        REST OF WORLD  GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.1.2        REST OF WORLD  ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.1.3        REST OF WORLD  GENE TRANSFER MARKET, BY THERAPY

6.5.2             REST OF WORLD CANCER GENE THERAPY, MARKET BY COUNTRY

6.5.2.1        BRAZIL

6.5.2.1.1        BRAZIL CANCER GENE THERAPY MARKET, BY THERAPY

6.5.2.1.1.1. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.2.1.1.2. BRAZIL ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.2.1.1.3. BRAZIL GENE TRANSFER MARKET, BY THERAPY

6.5.2.2        TURKEY

6.5.2.2.1        TURKEY CANCER GENE THERAPY MARKET, BY THERAPY

6.5.2.2.1.1. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.2.2.1.2. TURKEY ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.2.2.1.3. TURKEY GENE TRANSFER MARKET, BY THERAPY

6.5.2.3        SAUDI ARABIA

6.5.2.3.1        SAUDI ARABIA CANCER GENE THERAPY MARKET, BY THERAPY

6.5.2.3.1.1. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.2.3.1.2. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.2.3.1.3. SAUDI ARABIA GENE TRANSFER MARKET, BY THERAPY

6.5.2.4        SOUTH AFRICA

6.5.2.4.1        SOUTH AFRICA CANCER GENE THERAPY MARKET, BY THERAPY

6.5.2.4.1.1. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.2.4.1.2. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.2.4.1.3. SOUTH AFRICA GENE TRANSFER MARKET, BY THERAPY

6.5.2.5        REMAINING COUNTRIES

6.5.2.5.1        REMAINING COUNTRIES CANCER GENE THERAPY MARKET, BY THERAPY

6.5.2.5.1.1. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET, BY THERAPY

6.5.2.5.1.2. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET, BY THERAPY

6.5.2.5.1.3. REMAINING COUNTRIES GENE TRANSFER MARKET, BY THERAPY

7. COMPANY PROFILES

7.1.           ADAPTIMMUNE

7.1.1             COMPANY OVERVIEW

7.1.2             COMPANY SNAPSHOT

7.1.3             OPERATING BUSINESS SEGMENTS

7.1.4             PRODUCT PORTFOLIO

7.1.5             BUSINESS PERFORMANCE

7.1.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.2.           GLAXOSMITHKLINE

7.2.1             COMPANY OVERVIEW

7.2.2             COMPANY SNAPSHOT

7.2.3             OPERATING BUSINESS SEGMENTS

7.2.4             PRODUCT PORTFOLIO

7.2.5             BUSINESS PERFORMANCE

7.2.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.3.           BLUEBIRD BIO, INC.

7.3.1             COMPANY OVERVIEW

7.3.2             COMPANY SNAPSHOT

7.3.3             OPERATING BUSINESS SEGMENTS

7.3.4             PRODUCT PORTFOLIO

7.3.5             BUSINESS PERFORMANCE

7.3.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.4.           MERCK

7.4.1             COMPANY OVERVIEW

7.4.2             COMPANY SNAPSHOT

7.4.3             OPERATING BUSINESS SEGMENTS

7.4.4             PRODUCT PORTFOLIO

7.4.5             BUSINESS PERFORMANCE

7.4.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.5.           CELGENE

7.5.1             COMPANY OVERVIEW

7.5.2             COMPANY SNAPSHOT

7.5.3             OPERATING BUSINESS SEGMENTS

7.5.4             PRODUCT PORTFOLIO

7.5.5             BUSINESS PERFORMANCE

7.5.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.6.           SHANGHAI SUNWAY BIOTECH

7.6.1             COMPANY OVERVIEW

7.6.2             COMPANY SNAPSHOT

7.6.3             OPERATING BUSINESS SEGMENTS

7.6.4             PRODUCT PORTFOLIO

7.6.5             BUSINESS PERFORMANCE

7.6.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.7.           BIOCANCELL

7.7.1             COMPANY OVERVIEW

7.7.2             COMPANY SNAPSHOT

7.7.3             OPERATING BUSINESS SEGMENTS

7.7.4             PRODUCT PORTFOLIO

7.7.5             BUSINESS PERFORMANCE

7.7.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.8.           SHENZHEN SIBIONO GENETECH

7.8.1             COMPANY OVERVIEW

7.8.2             COMPANY SNAPSHOT

7.8.3             OPERATING BUSINESS SEGMENTS

7.8.4             PRODUCT PORTFOLIO

7.8.5             BUSINESS PERFORMANCE

7.8.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.9.           SYNERGENE THERAPEUTICS

7.9.1             COMPANY OVERVIEW

7.9.2             COMPANY SNAPSHOT

7.9.3             OPERATING BUSINESS SEGMENTS

7.9.4             PRODUCT PORTFOLIO

7.9.5             BUSINESS PERFORMANCE

7.9.6             KEY STRATEGIC MOVES AND DEVELOPMENT

7.10.         ONCOGENEX PHARMACEUTICALS

7.10.1           COMPANY OVERVIEW

7.10.2           COMPANY SNAPSHOT

7.10.3           OPERATING BUSINESS SEGMENTS

7.10.4           PRODUCT PORTFOLIO

7.10.5           BUSINESS PERFORMANCE

7.10.6            KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TABLES

TABLE 1. GLOBAL  CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 2. GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 3. ADENOVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 4. NORTH AMERICA ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 5. EUROPE ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. ASIA-PACIFIC ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 7. REST OF WORLD ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 8. LENTIVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 9. NORTH AMERICA LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 10. EUROPE LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 11. ASIA-PACIFIC LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 12. REST OF WORLD LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 13. RETRO VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 14. NORTH AMERICA RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 15. EUROPE RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 16. ASIA-PACIFIC RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 17. REST OF WORLD RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 18. ADENO ASSOCIATED VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 19. NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 20. EUROPE ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 21. ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 22. REST OF WORLD ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 23. HERPES SIMPLEX VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 24. NORTH AMERICA HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 25. EUROPE HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 26. ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 27. REST OF WORLD HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 28. ALPHA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 29. NORTH AMERICA ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 30. EUROPE ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 31. ASIA-PACIFIC ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 32. REST OF WORLD ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 33. VACCINIA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 34. NORTH AMERICA VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 35. EUROPE VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 36. ASIA-PACIFIC VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 37. REST OF WORLD VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 38. SIMIAN VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 39. NORTH AMERICA SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 40. EUROPE SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 41. ASIA-PACIFIC SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 42. REST OF WORLD SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 43. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 44. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 45. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 46. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 47. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 48. GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 49. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 50. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 51. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 52. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 53. GLOBAL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 54. DELIVERY OF CYTOKINES GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 55. NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 56. EUROPE DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 57. ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 58. REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 59. DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 60. NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 61. EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 62. ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 63. REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 64. ONCOLYTIC VIROTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 65. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 66. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 67. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 68. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 69. GLOBAL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 70. ELECTROPORATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 71. NORTH AMERICA ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 72. EUROPE ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 73. ASIA-PACIFIC ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 74. REST OF WORLD ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 75. SONOPORTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 76. NORTH AMERICA SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 77. EUROPE SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 78. ASIA-PACIFIC SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 79. REST OF WORLD SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 80. MAGNETOFECTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 81. NORTH AMERICA MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 82. EUROPE MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 83. ASIA-PACIFIC MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 84. REST OF WORLD MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 85. GENE GUN MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 86. NORTH AMERICA GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 87. EUROPE GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 88. ASIA-PACIFIC GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 89. REST OF WORLD GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 90. GENE TRANSFER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 91. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 92. EUROPE GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 93. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 94. REST OF WORLD GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

TABLE 95. GLOBAL  CANCER GENE THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

TABLE 96. NORTH AMERICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 97. NORTH AMERICA  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 98. NORTH AMERICA  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 99. NORTH AMERICA  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 100. U.S CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 101. U.S GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 102. U.S ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 103. U.S GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 104. CANADA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 105. CANADA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 106. CANADA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 107. CANADA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 108. MEXICO CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 109. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 110. MEXICO ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 111. MEXICO GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 112. EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 113. EUROPE  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 114. EUROPE  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 115. EUROPE  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 116. GERMANY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 117. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 118. GERMANY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 119. GERMANY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 120. FRANCE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 121. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 122. FRANCE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 123. FRANCE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 124. UK CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 125. UK GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 126. UK ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 127. UK GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 128. ITALY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 129. ITALY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 130. ITALY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 131. ITALY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 132. SPAIN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 133. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 134. SPAIN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 135. SPAIN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 136. REST OF EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 137. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 138. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 139. REST OF EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 140. ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 141. ASIA-PACIFIC  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 142. ASIA-PACIFIC  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 143. ASIA-PACIFIC  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 144. JAPAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 145. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 146. JAPAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 147. JAPAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 148. CHINA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 149. CHINA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 150. CHINA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 151. CHINA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 152. AUSTRALIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 153. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 154. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 155. AUSTRALIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 156. INDIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 157. INDIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 158. INDIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 159. INDIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 160. SOUTH KOREA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 161. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 162. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 163. SOUTH KOREA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 164. TAIWAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 165. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 166. TAIWAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 167. TAIWAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 168. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 169. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 170. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 171. REST OF ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 172. REST OF WORLD CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 173. REST OF WORLD  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 174. REST OF WORLD  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 175. REST OF WORLD  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 176. BRAZIL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 177. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 178. BRAZIL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 179. BRAZIL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 180. TURKEY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 181. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 182. TURKEY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 183. TURKEY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 184. SAUDI ARABIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 185. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 186. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 187. SAUDI ARABIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 188. SOUTH AFRICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 189. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 190. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 191. SOUTH AFRICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 192. REMAINING COUNTRIES CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 193. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 194. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 195. REMAINING COUNTRIES GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

TABLE 196. ADAPTIMMUNE: COMPANY SNAPSHOT

TABLE 197. ADAPTIMMUNE: OPERATING SEGMENTS

TABLE 198. ADAPTIMMUNE: PRODUCT PORTFOLIO

TABLE 199. ADAPTIMMUNE: KEY STRATERGY

TABLE 200. GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 201. GLAXOSMITHKLINE: OPERATING SEGMENTS

TABLE 202. GLAXOSMITHKLINE: PRODUCT PORTFOLIO

TABLE 203. GLAXOSMITHKLINE: KEY STRATERGY

TABLE 204. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT

TABLE 205. BLUEBIRD BIO, INC.: OPERATING SEGMENTS

TABLE 206. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO

TABLE 207. BLUEBIRD BIO, INC.: KEY STRATERGY

TABLE 208. MERCK: COMPANY SNAPSHOT

TABLE 209. MERCK: OPERATING SEGMENTS

TABLE 210. MERCK: PRODUCT PORTFOLIO

TABLE 211. MERCK: KEY STRATERGY

TABLE 212. CELGENE: COMPANY SNAPSHOT

TABLE 213. CELGENE: OPERATING SEGMENTS

TABLE 214. CELGENE: PRODUCT PORTFOLIO

TABLE 215. CELGENE: KEY STRATERGY

TABLE 216. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT

TABLE 217. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS

TABLE 218. SHANGHAI SUNWAY BIOTECH: PRODUCT PORTFOLIO

TABLE 219. SHANGHAI SUNWAY BIOTECH: KEY STRATERGY

TABLE 220. BIOCANCELL: COMPANY SNAPSHOT

TABLE 221. BIOCANCELL: OPERATING SEGMENTS

TABLE 222. BIOCANCELL: PRODUCT PORTFOLIO

TABLE 223. BIOCANCELL: KEY STRATERGY

TABLE 224. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT

TABLE 225. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS

TABLE 226. SHENZHEN SIBIONO GENETECH: PRODUCT PORTFOLIO

TABLE 227. SHENZHEN SIBIONO GENETECH: KEY STRATERGY

TABLE 228. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT

TABLE 229. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS

TABLE 230. SYNERGENE THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 231. SYNERGENE THERAPEUTICS: KEY STRATERGY

TABLE 232. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 233. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 234. ONCOGENEX PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 235. ONCOGENEX PHARMACEUTICALS: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. GLOBAL  CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 2. GLOBAL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 3. ADENOVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 4. NORTH AMERICA ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 5. EUROPE ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. ASIA-PACIFIC ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 7. REST OF WORLD ADENOVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 8. LENTIVIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 9. NORTH AMERICA LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 10. EUROPE LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 11. ASIA-PACIFIC LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 12. REST OF WORLD LENTIVIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 13. RETRO VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 14. NORTH AMERICA RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 15. EUROPE RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 16. ASIA-PACIFIC RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 17. REST OF WORLD RETRO VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 18. ADENO ASSOCIATED VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 19. NORTH AMERICA ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 20. EUROPE ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 21. ASIA-PACIFIC ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 22. REST OF WORLD ADENO ASSOCIATED VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 23. HERPES SIMPLEX VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 24. NORTH AMERICA HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 25. EUROPE HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 26. ASIA-PACIFIC HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 27. REST OF WORLD HERPES SIMPLEX VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 28. ALPHA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 29. NORTH AMERICA ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 30. EUROPE ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 31. ASIA-PACIFIC ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 32. REST OF WORLD ALPHA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 33. VACCINIA VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 34. NORTH AMERICA VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 35. EUROPE VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 36. ASIA-PACIFIC VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 37. REST OF WORLD VACCINIA VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 38. SIMIAN VIRUS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 39. NORTH AMERICA SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 40. EUROPE SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 41. ASIA-PACIFIC SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 42. REST OF WORLD SIMIAN VIRUS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 43. OTHERS MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 44. NORTH AMERICA OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 45. EUROPE OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 46. ASIA-PACIFIC OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 47. REST OF WORLD OTHERS MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 48. GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 49. NORTH AMERICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 50. EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 51. ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 52. REST OF WORLD GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 53. GLOBAL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 54. DELIVERY OF CYTOKINES GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 55. NORTH AMERICA DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 56. EUROPE DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 57. ASIA-PACIFIC DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 58. REST OF WORLD DELIVERY OF CYTOKINES GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 59. DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 60. NORTH AMERICA DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 61. EUROPE DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 62. ASIA-PACIFIC DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 63. REST OF WORLD DELIVERY OF TUMOR ANTIGEN GENE MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 64. ONCOLYTIC VIROTHERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 65. NORTH AMERICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 66. EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 67. ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 68. REST OF WORLD ONCOLYTIC VIROTHERAPY MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 69. GLOBAL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 70. ELECTROPORATION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 71. NORTH AMERICA ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 72. EUROPE ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 73. ASIA-PACIFIC ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 74. REST OF WORLD ELECTROPORATION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 75. SONOPORTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 76. NORTH AMERICA SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 77. EUROPE SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 78. ASIA-PACIFIC SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 79. REST OF WORLD SONOPORTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 80. MAGNETOFECTION MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 81. NORTH AMERICA MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 82. EUROPE MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 83. ASIA-PACIFIC MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 84. REST OF WORLD MAGNETOFECTION MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 85. GENE GUN MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 86. NORTH AMERICA GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 87. EUROPE GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 88. ASIA-PACIFIC GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 89. REST OF WORLD GENE GUN MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 90. GENE TRANSFER MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 91. NORTH AMERICA GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 92. EUROPE GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 93. ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 94. REST OF WORLD GENE TRANSFER MARKET VALUE, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 95. GLOBAL  CANCER GENE THERAPY MARKET VALUE, BY REGION, 2022-2030, MILLION USD

FIGURE 96. NORTH AMERICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 97. NORTH AMERICA  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 98. NORTH AMERICA  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 99. NORTH AMERICA  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 100. U.S CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 101. U.S GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 102. U.S ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 103. U.S GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 104. CANADA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 105. CANADA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 106. CANADA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 107. CANADA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 108. MEXICO CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 109. MEXICO GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 110. MEXICO ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 111. MEXICO GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 112. EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 113. EUROPE  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 114. EUROPE  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 115. EUROPE  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 116. GERMANY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 117. GERMANY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 118. GERMANY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 119. GERMANY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 120. FRANCE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 121. FRANCE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 122. FRANCE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 123. FRANCE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 124. UK CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 125. UK GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 126. UK ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 127. UK GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 128. ITALY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 129. ITALY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 130. ITALY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 131. ITALY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 132. SPAIN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 133. SPAIN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 134. SPAIN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 135. SPAIN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 136. REST OF EUROPE CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 137. REST OF EUROPE GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 138. REST OF EUROPE ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 139. REST OF EUROPE GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 140. ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 141. ASIA-PACIFIC  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 142. ASIA-PACIFIC  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 143. ASIA-PACIFIC  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 144. JAPAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 145. JAPAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 146. JAPAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 147. JAPAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 148. CHINA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 149. CHINA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 150. CHINA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 151. CHINA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 152. AUSTRALIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 153. AUSTRALIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 154. AUSTRALIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 155. AUSTRALIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 156. INDIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 157. INDIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 158. INDIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 159. INDIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 160. SOUTH KOREA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 161. SOUTH KOREA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 162. SOUTH KOREA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 163. SOUTH KOREA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 164. TAIWAN CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 165. TAIWAN GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 166. TAIWAN ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 167. TAIWAN GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 168. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 169. REST OF ASIA-PACIFIC GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 170. REST OF ASIA-PACIFIC ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 171. REST OF ASIA-PACIFIC GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 172. REST OF WORLD CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 173. REST OF WORLD  GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 174. REST OF WORLD  ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 175. REST OF WORLD  GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 176. BRAZIL CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 177. BRAZIL GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 178. BRAZIL ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 179. BRAZIL GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 180. TURKEY CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 181. TURKEY GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 182. TURKEY ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 183. TURKEY GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 184. SAUDI ARABIA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 185. SAUDI ARABIA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 186. SAUDI ARABIA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 187. SAUDI ARABIA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 188. SOUTH AFRICA CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 189. SOUTH AFRICA GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 190. SOUTH AFRICA ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 191. SOUTH AFRICA GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 192. REMAINING COUNTRIES CANCER GENE THERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 193. REMAINING COUNTRIES GENE INDUCED IMMUNOTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 194. REMAINING COUNTRIES ONCOLYTIC VIROTHERAPY MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 195. REMAINING COUNTRIES GENE TRANSFER MARKET VALUE, BY THERAPY, 2022-2030, MILLION USD

FIGURE 196. ADAPTIMMUNE: NET SALES,2017-2022

FIGURE 197. GLAXOSMITHKLINE: NET SALES,2017-2022

FIGURE 198. BLUEBIRD BIO, INC.: NET SALES,2017-2022

FIGURE 199. MERCK: NET SALES,2017-2022

FIGURE 200. CELGENE: NET SALES,2017-2022

FIGURE 201. SHANGHAI SUNWAY BIOTECH: NET SALES,2017-2022

FIGURE 202. BIOCANCELL: NET SALES,2017-2022

FIGURE 203. SHENZHEN SIBIONO GENETECH: NET SALES,2017-2022

FIGURE 204. SYNERGENE THERAPEUTICS: NET SALES,2017-2022

FIGURE 205. ONCOGENEX PHARMACEUTICALS: NET SALES,2017-2022

 

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

 

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

              

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.